Finally - hope to stop the terrible PF cough…

Respivant Sciences is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of patients suffering from respiratory diseases.

Approximately 75% of IPF patients have a persistent chronic cough, and most of these patients do not respond to currently available medicines (refractory). IPF patients can cough up to 100 times per hour on average, which can lead to laryngeal trauma, chest pain, headache, incontinence, vomiting, anxiety, depression, and other morbidities. Additionally, this unrelenting cough contributes to breathlessness and fatigue, the other two prevalent conditions of IPF.

SCENIC is a clinical trial designed to assess the potential of a new inhaled therapy to significantly reduce cough and improve quality of life for those with IPF. Participation in this clinical trial may help IPF patients with this often-debilitating condition and could lead to the first therapy approved for IPF patients with chronic cough. https://www.scenictrial.com/

You may qualify for the SCENIC clinical trial if you:

• Have been diagnosed with IPF and are 40-89 years old
• Have a moderate-to-severe persistent cough that is primarily due to IPF
• Do not have any other serious medical condition, are not participating in another clinical trial, not expected to have a lung transplant within the next twelve months, and not currently smoking

For more information on the study, please visit https://clinicaltrials.gov or https://scenictrial.com/